ZFIN ID: ZDB-FISH-150901-28226
Fish name: WT + MO1-tbxta
Genotype: WT
Targeting Reagent: MO1-tbxta
HUMAN DISEASE MODELED by WT + MO1-tbxta
No data available
GENE EXPRESSION
Gene expression in WT + MO1-tbxta
RNA expression
Expressed Gene Structure Conditions Figures
dand5 standard conditions Fig. 1 with imageFig. 2 with imageFig. 3 with image from Gourronc et al., 2007
enc3 standard conditions Fig. 4 with image from Qian et al., 2013
fgf3 standard conditions Fig. 4 with image from Osborn et al., 2020
fgf4 standard conditions Fig. 4 with image from Osborn et al., 2020
fgf8a standard conditions Fig. 4 with image from Osborn et al., 2020
lft1 standard conditions Fig. 3 from Amack et al., 2004
lft2 standard conditions Fig. 3 from Amack et al., 2004
myf5 standard conditions Fig. 4 with image from Osborn et al., 2020
chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
myod1 standard conditions Fig. 4 with image from Osborn et al., 2020
chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
nphs1 standard conditions Fig. 8 with image from Huang et al., 2013
nphs2 standard conditions Fig. 8 with image from Huang et al., 2013
pdia6 standard conditions Fig. 2 with image from Gourronc et al., 2007
pitx2 standard conditions Fig. 4 from Burdine et al., 2016
shha standard conditions Fig. 2 with image from Gourronc et al., 2007
slc20a1a standard conditions Fig. 8 with image from Huang et al., 2013
spaw standard conditions Fig. 4 with image from Pelliccia et al., 2017
Fig. 2 with image from Gourronc et al., 2007
tbxta standard conditions Fig. 2 with imageFig. 3 with image from Gourronc et al., 2007
Fig. 2 from Amack et al., 2004
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + MO1-tbxta
Phenotype Conditions Figures
adaxial cell myf5 expression decreased distribution, abnormal chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
axial chorda mesoderm fgf8a expression absent, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
calmodulin-dependent protein kinase activity decreased rate, abnormal standard conditions Fig. 7 with image from Francescatto et al., 2010
determination of heart left/right asymmetry disrupted, abnormal standard conditions Fig. 2 with image from Hatler et al., 2009
epithalamus determination of left/right symmetry disrupted, abnormal standard conditions Fig. T1 with image from Roussigné et al., 2009
habenula determination of left/right symmetry disrupted, abnormal standard conditions Fig. 5 with image from Roussigné et al., 2009
habenula neurogenesis process quality, abnormal standard conditions Fig. 5 with image from Roussigné et al., 2009
heart looping disrupted, abnormal standard conditions Fig. 2 with image from Hatler et al., 2009
heart tube mislocalised radially, abnormal standard conditions Fig. 2 with image from Hatler et al., 2009
lateral plate mesoderm right side spaw expression mislocalised, abnormal control Fig. 4 with image from Pelliccia et al., 2017
margin fgf8a expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
nodal signaling pathway involved in determination of left/right asymmetry disrupted, abnormal standard conditions Fig. 5 with image from Roussigné et al., 2009
notochord posterior-most region fgf4 expression absent, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
notochord posterior-most region fgf3 expression absent, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
notochord posterior-most region fgf8a expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
post-vent region aplastic, abnormal standard conditions Fig. 5 with image from Robu et al., 2007
presumptive paraxial mesoderm myod1 expression absent, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
presumptive paraxial mesoderm myf5 expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
protein autophosphorylation arrested, abnormal standard conditions Fig. 7 with image from Francescatto et al., 2010
segmental plate adaxial cell myod1 expression absent, abnormal chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
segmental plate adaxial cell myod1 expression absent, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
segmental plate adaxial cell myf5 expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
somite adaxial cell myod1 expression absent, abnormal chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
somite adaxial cell myod1 expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
tail bud myod1 expression absent, abnormal chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
tail bud myf5 expression decreased distribution, abnormal standard conditions Fig. 4 with image from Osborn et al., 2020
tail bud myf5 expression increased amount, abnormal chemical treatment: Cyclopamine Fig. 4 with image from Osborn et al., 2020
whole organism decreased length, abnormal standard conditions Fig. 4 from Burdine et al., 2016

CITATIONS  (12)